{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:07:56Z","timestamp":1774314476756,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoimmune blistering diseases (AIBDs) may occur as adverse effects of various therapies, including biologics. Data on their association with IL-23 inhibitors in ulcerative colitis (UC) remain limited. We report the case of a 59-year-old man with UC who developed pruritic cutaneous bullae emerging within days following mirikizumab infusion. Histopathological examination and direct immunofluorescence demonstrated findings consistent with an AIBD. Following the withdrawal of mirikizumab, the residual cutaneous lesions progressively improved under corticosteroid therapy, suggesting a temporal association with the biologic exposure. This case highlights that mirikizumab may represent a potential trigger of an AIBD in susceptible individuals with UC. Clinicians should be aware of this rare but relevant complication to ensure timely recognition and management.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaf235","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:35:55Z","timestamp":1770122155000},"source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous autoimmune blistering disease during mirikizumab therapy in a patient with ulcerative colitis: a new potential trigger?"],"prefix":"10.1093","volume":"20","author":[{"given":"Lucia","family":"Centanni","sequence":"first","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital Department of , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University Faculty of Medicine and Surgery, Department of Gastroenterology and Endoscopy, , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital Department of , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University Faculty of Medicine and Surgery, Department of Gastroenterology and Endoscopy, , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital Department of , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital Department of , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University Faculty of Medicine and Surgery, Department of Gastroenterology and Endoscopy, , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026021700561588700_jjaf235-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026021700561588700_jjaf235-B2","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s13555-025-01444-9","article-title":"A narrative review of pemphigoid diseases: bridging associations, comorbidities, and management","volume":"15","author":"Myers","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026021700561588700_jjaf235-B3","doi-asserted-by":"publisher","first-page":"adv00057","DOI":"10.2340\/00015555-3408","article-title":"Bullous drug reactions","volume":"100","author":"Mockenhaupt","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026021700561588700_jjaf235-B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000489163","article-title":"Bullous pemphigoid associated with adalimumab therapy in a patient with ulcerative colitis","volume":"10","author":"Hoffmann","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"2026021700561588700_jjaf235-B5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2026021700561588700_jjaf235-B6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026021700561588700_jjaf235-B7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res"},{"key":"2026021700561588700_jjaf235-B8","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-associated bullous pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026021700561588700_jjaf235-B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026021700561588700_jjaf235-B10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"2026021700561588700_jjaf235-B11","doi-asserted-by":"publisher","first-page":"e15207","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: a case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026021700561588700_jjaf235-B12","doi-asserted-by":"publisher","first-page":"e72\u20133","DOI":"10.1111\/1346-8138.16534","article-title":"Bullous pemphigoid during the treatment of psoriasis vulgaris with risankizumab","volume":"50","author":"Fukada","year":"2023","journal-title":"J Dermatol"},{"key":"2026021700561588700_jjaf235-B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"2026021700561588700_jjaf235-B14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40265-023-01909-","article-title":"Mirikizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2026021700561588700_jjaf235-B15","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3389\/fimmu.2019.02327","article-title":"Genetics and omics analysis of autoimmune skin blistering diseases","volume":"10","author":"Olbrich","year":"2019","journal-title":"Front Immunol"},{"key":"2026021700561588700_jjaf235-B16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/tan.12960","article-title":"A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?","volume":"89","author":"Amber","year":"2017","journal-title":"HLA"},{"key":"2026021700561588700_jjaf235-B17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/2013.jamadermatol.729","article-title":"Worsening of bullous pemphigoid following Bacillus Calmette-Gu\u00e9rin treatment for bladder cancer","volume":"149","author":"Johnson","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026021700561588700_jjaf235-B18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026021700561588700_jjaf235-B19","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026021700561588700_jjaf235-B20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ced\/llac077","article-title":"Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease","volume":"48","author":"Gambichler","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2026021700561588700_jjaf235-B21","doi-asserted-by":"publisher","first-page":"e23496","DOI":"10.1097\/MD.0000000000023496","article-title":"Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy","volume":"99","author":"Wu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026021700561588700_jjaf235-B22","doi-asserted-by":"publisher","first-page":"1050373","DOI":"10.3389\/fimmu.2022.1050373","article-title":"Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2026021700561588700_jjaf235-B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ejhpharm-2018-001849","article-title":"Bullous pemphigoid induced by ustekinumab: a case report","volume":"28","author":"Marin","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"2026021700561588700_jjaf235-B24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ddg.14199","article-title":"Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab","volume":"19","author":"Querol-Cisneros","year":"2021","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"2026021700561588700_jjaf235-B25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4274\/turkderm.galenos.2018.11354","article-title":"Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature","volume":"53","author":"Vural","year":"2019","journal-title":"TURKDERM"},{"key":"2026021700561588700_jjaf235-B26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1684\/ejd.2016.2888","article-title":"Bullous pemphigoid during ustekinumab therapy in a psoriatic patient","volume":"27","author":"Onsun","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2026021700561588700_jjaf235-B27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","article-title":"Bullous pemphigoid during ustekinumab therapy","volume":"1","author":"Le Guern","year":"2015","journal-title":"JAAD Case Rep"},{"key":"2026021700561588700_jjaf235-B28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/1346-8138.12943","article-title":"Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab","volume":"42","author":"Nakayama","year":"2015","journal-title":"J Dermatol"},{"key":"2026021700561588700_jjaf235-B29","year":"2023"},{"key":"2026021700561588700_jjaf235-B30","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Pl\u00e9e","year":"2015","journal-title":"Sci Rep"},{"key":"2026021700561588700_jjaf235-B31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2026021700561588700_jjaf235-B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the Interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"2026021700561588700_jjaf235-B33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026021700561588700_jjaf235-B34","doi-asserted-by":"publisher","first-page":"103500","DOI":"10.1016\/j.jaut.2025.103500","article-title":"The pivotal role of Interleukin-23 in the skin-gut-joint axis","volume":"157","author":"Zabotti","year":"2025","journal-title":"J Autoimmun"},{"key":"2026021700561588700_jjaf235-B35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.47102\/annals-acadmedsg.V44N4p119","article-title":"Anti-BP180 NC16A IgG Titres as an Indicator of disease activity and outcome in Asian patients with bullous pemphigoid","volume":"44","author":"Cai","year":"2015","journal-title":"Ann Acad Med Singap"},{"key":"2026021700561588700_jjaf235-B36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1346-8138.2004.tb00689.x","article-title":"Monitoring of ELISA for Anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid","volume":"31","author":"Izumi","year":"2004","journal-title":"J Dermatol"},{"key":"2026021700561588700_jjaf235-B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Crohn\u2019s and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf235\/66893585\/jjaf235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf235\/66893585\/jjaf235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf235\/66893585\/jjaf235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:56:23Z","timestamp":1771307783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf235\/8483050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf235","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"jjaf235"}}